SULT1A1 enzyme booster to amplify topical minoxidil response in androgenic alopecia: a single-center prospective study

B. S. Chandrashekar; Madura Chandu; Chaithra Shenoy; Abhijna Chandar; M. S. Roopa

doi:10.18203/2320-6012.ijrms20243362

Authors

B. S. Chandrashekar Department of Clinical Research, CUTIS Academy of Cutaneous Sciences, Bangalore, Karnataka, India
Madura Chandu Department of Clinical Research, CUTIS Academy of Cutaneous Sciences, Bangalore, Karnataka, India
Chaithra Shenoy Department of Clinical Research, CUTIS Academy of Cutaneous Sciences, Bangalore, Karnataka, India
Abhijna Chandar Department of Clinical Research, CUTIS Academy of Cutaneous Sciences, Bangalore, Karnataka, India
M. S. Roopa Department of Clinical Research, CUTIS Academy of Cutaneous Sciences, Bangalore, Karnataka, India

DOI:

https://doi.org/10.18203/2320-6012.ijrms20243362

Keywords:

Topical minoxidil, Sulfotransferase, minoxidil booster, Androgenetic alopecia, Minoxidil booster

Abstract

Background: Androgenetic alopecia (AGA) is a common hair loss disorder affecting individuals across all demographics. Minoxidil, the most widely used treatment for AGA, has limited efficacy, benefiting only 30-40% of users. Previous studies have linked minoxidil's effectiveness to the sulfotransferase enzyme (SULT1A1) in hair follicles, suggesting that boosting this enzyme's activity may improve treatment outcomes in non-responders.

Methods: This study aimed to evaluate the effect of a SULT1A1 enzyme booster in enhancing minoxidil response among AGA patients with limited prior improvement. The study enrolled 101 AGA patients who were non-responders to 5% topical minoxidil. Participants were treated with a combination of SULT1A1 adjuvant solution and 5% topical minoxidil for 90 days. Treatment response was evaluated using clinical assessment and statistical analysis to determine the impact of gender and age on outcomes.

Results: After 90 days of treatment, 65% of the patients exhibited a positive response to the combination therapy. Gender analysis showed a significantly higher positive response in females compared to males (p<0.05). However, age did not significantly influence treatment outcomes.

Conclusion: The combination of SULT1A1 enzyme booster and minoxidil demonstrated a promising increase in response among AGA patients who previously showed limited improvement with minoxidil alone. This study contributes to the limited literature on minoxidil booster responses in AGA, offering hope for improved treatment regimens for affected individuals.

Metrics

Metrics Loading ...

References

Shankar DK, Chakravarthi M, Shilpakar R. Male androgenetic alopecia: Population-based study in 1,005 subjects. Int J Trichol. 2009;1:131-3.

Mantovani GP, Marra C, De Maria F, Pinto V, De Santis G. Adipose-derived stromal vascular fraction (SVF) for the treatment of androgenic alopecia (AGA): a systematic review. Acta Biomed. 2023;17(5):2023236.

Shadi, Z. Compliance to topical minoxidil and reasons for discontinuation among patients with Androgenetic Alopecia. Dermatol Ther (Heidelb). 2023;13:1157-69.

Dhurat R, Daruwalla S, Pai S. SULT1A1 (Minoxidil Sulfotransferase) enzyme booster significantly improves response to topical minoxidil for hair regrowth. J Cosmet Dermatol. 2021;4:1–4.

Goren A, Castano JA, McCoy J, Bmudez F, Lotti, T. Novel enzymatic assay predicts minoxidil response in the treatment of androgenetic alopecia. Dermatologic Therapy. 2013;27(3):171–3.

Mehta N, Huang S, Dhura R. Minoxidil sulfotransferase enzymatical activity in plants: A novel paradigm in increasing minoxidil response in androgenetic alopecia. J Cosmet Dermatol. 2023;10:1-5.

Ramos PM, McCoy J, Wambier C, Shapiro J, Vañó-Galvan S, Sinclair R, et al. Novel topical booster enhances follicular sulfotransferase activity in patients with androgenetic alopecia: a new strategy to improve minoxidil response. J Eur Acad Dermatol Venereol. 2020;34(12):799-800.

Roberts J, Desai N, McCoy J, Goren A. Sulfotransferase activity in plucked hair follicles predicts response to topical minoxidil in the treatment of female androgenetic alopecia. Dermatol Ther. 2014;27(4):252-4.

Hebbring SJ, Adjei AA, Baer JL, Jenkins GD, Zhang J, Cunningham JM, et al. Human SULT1A1 gene: copy number differences and functional implications. Hum Mol Genet. 2007;1;16(5):463-70.

Tyapochkin E, Cook PF, Chen G. para-Nitrophenyl sulfate activation of human sulfotransferase 1A1 is consistent with intercepting the middle dot PAP complex and reformation of E middle dot PAPS. J Biol Chem. 2009;23;284(43):29357-64.

Paul P, Suwan J, Liu J, Dordick JS, Linhardt RJ. Recent advances in sulfotransferase enzyme activity assays. Anal Bioanal Chem. 2012;403(6):1491-500.

Johnson GA, Baker CA, Knight KA. Minoxidil sulfotransferase, a marker of human keratinocyte differentiation. J Invest Dermatol. 1992;98(5):730-3.

Pietrauszka K, Bergler-Czop B. Sulfotransferase SULT1A1 activity in hair follicle, a prognostic marker of response to the minoxidil treatment in patients with androgenetic alopecia: a review. Postepy Dermatol Alergol. 2022;39(3):472-478..

Daniels J, Kadlubar S. Pharmacogenetics of SULT1A1. Pharmacogenomics. 2014;15(14):1823-38.